Glucagon-like-peptide-1 Receptor Agonists in Patients Receiving Maintenance Dialysis
NCT07017270 on ClinicalTrials.gov · last registry update 2026-06-26
Recruiting now, toward 100 participants. Due to report July 2027, alongside 39 other tracked readouts that quarter. Primary outcome, as filed: Adherence of Study Intervention. Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is approved in the US, but not for diabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.
- Status
- RECRUITING
- Phase
- P4
- Drug
- semaglutideRybelsus, Wegovy, Ozempic
- Sponsor
- Unity Health Toronto
- Sponsor type
- Other
- Enrollment
- 100
- Started
- 2025-11-27
- Primary completion
- 2027-07 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Adherence of Study Intervention
Conditions studied
Kidney Disease, Chronic · Diabetes · Dialysis · End Stage Kidney Disease (ESRD)
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.